S&P 500   5,123.41
DOW   37,983.24
QQQ   438.27
5 Trends You Need to Know This Quarter
MarketBeat Week in Review – 4/8 - 4/12
Diplomat tapped as Latvia's new foreign minister as incumbent quits following flights scandal
It's almost April 15. Here's how to reduce stress and get your taxes done
Germany's Scholz arrives in China on a visit marked by trade tensions and Ukraine conflict
India's Modi vows to boost social spending, make country into a manufacturing hub ahead of election
Israel hails 'success' in blocking Iran's unprecedented attack. Biden now seeks diplomatic response
S&P 500   5,123.41
DOW   37,983.24
QQQ   438.27
5 Trends You Need to Know This Quarter
MarketBeat Week in Review – 4/8 - 4/12
Diplomat tapped as Latvia's new foreign minister as incumbent quits following flights scandal
It's almost April 15. Here's how to reduce stress and get your taxes done
Germany's Scholz arrives in China on a visit marked by trade tensions and Ukraine conflict
India's Modi vows to boost social spending, make country into a manufacturing hub ahead of election
Israel hails 'success' in blocking Iran's unprecedented attack. Biden now seeks diplomatic response
S&P 500   5,123.41
DOW   37,983.24
QQQ   438.27
5 Trends You Need to Know This Quarter
MarketBeat Week in Review – 4/8 - 4/12
Diplomat tapped as Latvia's new foreign minister as incumbent quits following flights scandal
It's almost April 15. Here's how to reduce stress and get your taxes done
Germany's Scholz arrives in China on a visit marked by trade tensions and Ukraine conflict
India's Modi vows to boost social spending, make country into a manufacturing hub ahead of election
Israel hails 'success' in blocking Iran's unprecedented attack. Biden now seeks diplomatic response
S&P 500   5,123.41
DOW   37,983.24
QQQ   438.27
5 Trends You Need to Know This Quarter
MarketBeat Week in Review – 4/8 - 4/12
Diplomat tapped as Latvia's new foreign minister as incumbent quits following flights scandal
It's almost April 15. Here's how to reduce stress and get your taxes done
Germany's Scholz arrives in China on a visit marked by trade tensions and Ukraine conflict
India's Modi vows to boost social spending, make country into a manufacturing hub ahead of election
Israel hails 'success' in blocking Iran's unprecedented attack. Biden now seeks diplomatic response
NASDAQ:IVVD

Invivyd (IVVD) Stock Price, News & Analysis

$2.95
-0.10 (-3.28%)
(As of 04/12/2024 ET)
Today's Range
$2.87
$3.12
50-Day Range
$2.95
$5.04
52-Week Range
$0.98
$5.20
Volume
921,593 shs
Average Volume
1.13 million shs
Market Capitalization
$351.70 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$11.33

Invivyd MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
284.2% Upside
$11.33 Price Target
Short Interest
Healthy
3.85% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
-0.01mentions of Invivyd in the last 14 days
Based on 10 Articles This Week
Insider Trading
Selling Shares
$19.75 M Sold Last Quarter
Proj. Earnings Growth
Growing
From ($0.74) to ($0.14) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.79 out of 5 stars

Medical Sector

378th out of 926 stocks

Biological Products, Except Diagnostic Industry

53rd out of 152 stocks

IVVD stock logo

About Invivyd Stock (NASDAQ:IVVD)

Invivyd, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company's lead product candidate is adintrevimab, a neutralizing antibody that is in Phase 3 clinical trials for the treatment and prevention of coronavirus disease, as well as developing monoclonal antibody candidates, including VYD222 and VYD224, which provides neutralizing protection against SARS-CoV-2. It also has discovery stage candidates for the prevention of seasonal influenza. Invivyd, Inc. has a collaboration agreement with Adimab, LLC for the discovery and optimization of proprietary antibodies; and the Scripps Research Institute to perform research activities to identify vaccine candidates for the prevention, diagnosis or treatment of influenza or beta coronaviruses. The company was formerly known as Adagio Therapeutics, Inc. and changed its name to Invivyd, Inc. in September 2022. Invivyd, Inc. was incorporated in 2020 and is headquartered in Waltham, Massachusetts.

IVVD Stock Price History

IVVD Stock News Headlines

Bitcoin Rockets To Record High But Buy THIS Instead
Recently, Bitcoin smashed through its previous record high to hit $72,720. It’s made many, many people very rich. But one cryptocurrency expert and investing millionaire is declaring…
Invivyd Appoints Jeremy Gowler As Interim CEO As Dave Hering Resigns
Invivyd Announces CEO Transition
Invivyd (NASDAQ:IVVD) Upgraded to "Buy" at Guggenheim
Bitcoin Rockets To Record High But Buy THIS Instead
Recently, Bitcoin smashed through its previous record high to hit $72,720. It’s made many, many people very rich. But one cryptocurrency expert and investing millionaire is declaring…
Invivyd: Q4 Earnings Insights
IVVD Stock Earnings: Invivyd Misses EPS for Q4 2023
Ligand Pharmaceuticals Incorporated
Invivyd Stock (NASDAQ:IVVD), Short Interest Report
See More Headlines
Receive IVVD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Invivyd and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Today
4/13/2024
Next Earnings (Estimated)
5/09/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:IVVD
Fax
N/A
Employees
84
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$11.33
High Stock Price Target
$15.00
Low Stock Price Target
$9.00
Potential Upside/Downside
+284.2%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

Net Income
$-198,640,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$1.61 per share

Miscellaneous

Free Float
96,450,000
Market Cap
$351.70 million
Optionable
Optionable
Beta
0.63
7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed Investors Cover

As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.

Get This Free Report

Key Executives

  • Mr. David Hering M.B.A. (Age 48)
    CEO & Director
    Comp: $932.5k
  • Ms. Jill Andersen J.D. (Age 51)
    Chief Legal Officer & Corporate Secretary
    Comp: $619.33k
  • Mr. William E. Duke Jr. (Age 52)
    M.B.A., Chief Financial Officer
  • Mr. Jeremy Gowler (Age 47)
    Chief Operating Officer & Chief Commercial Officer
  • Ms. Stacy Price M.S. (Age 55)
    Chief Technology & Manufacturing Officer
  • Dr. Robert D. Allen Ph.D.
    Chief Scientific Officer

IVVD Stock Analysis - Frequently Asked Questions

Should I buy or sell Invivyd stock right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Invivyd in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" IVVD shares.
View IVVD analyst ratings
or view top-rated stocks.

What is Invivyd's stock price target for 2024?

3 Wall Street analysts have issued 1-year target prices for Invivyd's stock. Their IVVD share price targets range from $9.00 to $15.00. On average, they predict the company's stock price to reach $11.33 in the next year. This suggests a possible upside of 284.2% from the stock's current price.
View analysts price targets for IVVD
or view top-rated stocks among Wall Street analysts.

How have IVVD shares performed in 2024?

Invivyd's stock was trading at $3.94 on January 1st, 2024. Since then, IVVD stock has decreased by 25.1% and is now trading at $2.95.
View the best growth stocks for 2024 here
.

Are investors shorting Invivyd?

Invivyd saw a increase in short interest in March. As of March 31st, there was short interest totaling 2,320,000 shares, an increase of 41.5% from the March 15th total of 1,640,000 shares. Based on an average trading volume of 836,800 shares, the short-interest ratio is currently 2.8 days. Approximately 3.9% of the company's stock are sold short.
View Invivyd's Short Interest
.

When is Invivyd's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024.
View our IVVD earnings forecast
.

What ETF holds Invivyd's stock?

Amplify Treatments, Testing and Advancements ETF holds 30,909 shares of IVVD stock, representing 0.32% of its portfolio.

How do I buy shares of Invivyd?

Shares of IVVD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:IVVD) was last updated on 4/14/2024 by MarketBeat.com Staff

From Our Partners